Skip to content

Influence of Microfiltered-seawater Supplementation and Variable Resistance Training in Blood Pressure, Oxidative Stress, Hepatic, and Renal Biomarkers in Older Women

Could Microfiltered-seawater Supplementation and Variable Resistance Training Improve Blood Pressure, Oxidative Stress, Hepatic, and Renal Biomarkers in Older Women? a 32-week, Double-blinded, Randomized, Placebo-controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06600243
Enrollment
109
Registered
2024-09-19
Start date
2014-05-31
Completion date
2015-07-31
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Hepatic Impairment, Oxidative Stress, Renal Disease

Keywords

aged, postmenopause, bone mineral density, muscle strength

Brief summary

This study was conducted to investigate the effects of the intake of deep sea water prior to resistance training on blood pressure, oxidative stress and hepatic and renal variables in older women.

Detailed description

This study was a 32 weeks, double-blinded, randomized, placebo-controlled trial.

Interventions

DIETARY_SUPPLEMENTResistance training + deep sea water

A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water

DIETARY_SUPPLEMENTResistance training + Placebo

A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation

DIETARY_SUPPLEMENTControl + deep sea water

A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water

DIETARY_SUPPLEMENTControl + Placebo

A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation

Sponsors

University of Valencia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* (i) women aged ≥65years * (ii) able to climb 10 stairs without pause and walk 100m without a walker * (iii) score above 23 points in the mini-mental state examination * (iv) \<1h of physical activity per week throughout the six months before the study * (v) possess a medical certificate of aptitude to carry out physical activity

Exclusion criteria

Participants who had suffered: * (i) any type of musculoskeletal, cardiovascular, hepatic, renal, pulmonary, neurological, or neuromuscular injury or disorder and/or * (ii) taking any type of drug/supplement that may alter the results of the study (e.g., vitamin C, vitamin E, estrogens, beta-blockers, calcitonin, steroid hormones, etc.) * (iii) changes in body weight of more than 10% in the year prior to the study * (iv) have a severe hearing or visual impairment * (v) participate in another research project (within the last six months) involving an exercise, dietetic and/or pharmaceutical intervention

Design outcomes

Primary

MeasureTime frameDescription
Malondialdehyde (MDA)pre (week 0) and post (week 32)Oxidative stress biomarker
Oxidized/reduced glutathione ratio (GSH/GSSG)pre (week 0) and post (week 32)Antioxidant enzyme
Interleukin-6 (IL-6)pre (week 0) and post (week 32)Inflammatory biomarker
Vitamin Dpre (week 0) and post (week 32)Vitamin

Secondary

MeasureTime frameDescription
Systolic blood pressure (SBP)pre (week 0) and post (week 32)Cardiovascular measure
Diastolic blood pressure (SBP)pre (week 0) and post (week 32)Cardiovascular measure
Up and Go test (UGT)pre (week 0) and post (week 32)Functional test
Agepre (week 0) and post (week 32)Sample demographic description
Glutamic-oxaloacetic transaminase (GOT)pre (week 0) and post (week 32)Hepatic biomarker
Weightpre (week 0) and post (week 32)Sample demographic description
Body mass index (BMI)pre (week 0) and post (week 32)Sample demographic description
Fat mass percentage (% fat mass)pre (week 0) and post (week 32)Sample demographic description
Heightpre (week 0) and post (week 32)Sample demographic description
Glutamic-pyruvic transaminase (GPT)pre (week 0) and post (week 32)Hepatic biomarker
Gamma- glutamyl transpeptidase (GGT)pre (week 0) and post (week 32)Hepatic biomarker
Alkaline phosphatase enzyme (ALP)pre (week 0) and post (week 32)Hepatic biomarker

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026